Accelerating research and development: The competitive advantage of clinical trials in Australia

What you’ll learn

• Understanding Australia’s strategic advantages for early phase product development

• Applying these advantages to optimise a regulatory and clinical development strategy

• An understanding of the Australian R&D Tax Incentive, including the available benefits and program requirements.

Description
Australia is an attractive destination to accelerate clinical development while maximising capital efficiency, providing streamlined regulatory pathways, high-quality research infrastructure, globally recognised data, and financial incentives designed to support innovation.

This webinar will explore the strategic advantages of conducting clinical trials in Australia, providing practical insights into how Australia’s clinical trial environment can help:

Accelerate time to first-in-human and proof-of-concept
Extend cash runway and improve capital efficiency
Reduce development risk through an established regulatory framework
Enhance global credibility with internationally accepted trial data
Whether you are planning your first clinical study or evaluating global trial jurisdictions, this session will provide practical guidance to support informed decision-making.

Looking to learn something new before your next live event? Explore our on-demand video library and access over 30 bite-sized videos packed with practical advice and expert insights.

Speakers
Matt McCarthy
Director | Global Investment and Innovation Incentives (Gi3), Deloitte

Matt is a Director in Deloitte's Global Investment and Innovation Incentives (Gi3) team with key expertise in the Life Sciences sector. Leveraging a background in Medical Science and as a Chartered Accountant, Matt has extensive experience in supporting global entities establish a presence in Australia for the conduct of clinical trials. Matt was previously awarded the top specialist consultant in Australia in the Accountants Daily 30 under 30 awards and holds numerous additional industry positions, including being a member of the national Clinical Trial R&D Task Force and Chair of the BioNSW Commercialisation Committee.

Leanne West
Principal Consultant, Scendea

Leanne West Is a Principal Consultant at Scendea responsible for providing regulatory and clinical development strategies to clients. Leanne has over 30 years’ experience in the biotechnology, pharmaceutical and CRO industries. Leanne has a broad level of experience across all phases of drug development and project management.

Therapeutic areas include Infectious disease, oncology, women’s health, cardiovascular disease and vaccines. Leanne has expertise in first-In-human trials and the regulatory hurdles required to move new agents into the clinic. Leanne has held senior positions at Prescient Therapeutics, Novotech, Clinical Network Services and Novogen Limited and has also consulted multiple biotechnology companies to facilitate their clinical development. Leanne holds a BBiotechnology (Hons).